Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-Stimulating Agents in Oncology

By Glaspy John A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 565-575

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

By Abraham Ivo   MacDonald Karen  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

Hemoglobin Decline in Chemotherapy Patients Prior To and After Policy Changes Affecting Use of Erythropoiesis-stimulating Agents: 2006 – 2009

By Hill JW   Cong Z   Hess G   McGarvey N   Nordyke RJ  

The Journal of International Medical Research, Vol. 40, Iss. 4, 2012-07 ,pp. : 1532-1545

Field House Publishing

Access to resources Recommend Favorite

Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents

By Mei Sheng Duh  

PharmacoEconomics, Vol. 26, Iss. 2, 2008-01 ,pp. : 99-120

Adis International

Access to resources Recommend Favorite